top2a: A Potential Drug Target and Biomarker for DNA Topoisomerase (ATP-Hydrolyzing)

Target Name: TOP2A

NCBI ID: G7153

TOP2A

top2a: A Potential Drug Target and Biomarker for DNA Topoisomerase (ATP-Hydrolyzing)

DNA topoisomerase (ATP-hydrolyzing) is a key enzyme in the process of DNA replication, which is crucial for the growth and development of all living organisms. This enzyme catalyzes the conversion of ATP to ADP and Pi, and is essential for the orderly replication of DNA in the cell. Mutations in the DNA topoisomerase gene have been linked to various genetic disorders, including cancer. Therefore, the study of DNA topoisomerase (ATP-hydrolyzing) has become an important field of research, and the discovery of new drug targets and biomarkers for this enzyme has significant implications for cancer treatment.

TOP2A: A Potential Drug Target

The topoisomerase (ATP-hydrolyzing) enzyme has been identified as a potential drug target in the field of cancer. Several studies have shown that inhibitors of ATP-hydrolyzing can cause a regression in the growth of various cancer cells, suggesting that this enzyme may play a significant role in the development and progression of cancer. In addition, several drugs that inhibit ATP-hydrolyzing have been shown to be effective in treating various types of cancer, including breast, ovarian, and prostate cancers.

TOP2A: A Potential Biomarker

DNA topoisomerase (ATP-hydrolyzing) has also been identified as a potential biomarker for cancer. The expression of ATP-hydrolyzing is regulated by various factors, including growth conditions, DNA replication, and cellular stress. Therefore, the levels of ATP-hydrolyzing can be used as a marker for the diagnosis and prognosis of cancer. Several studies have shown that the expression of ATP-hydrolyzing is significantly increased in various types of cancer, including breast, ovarian, and prostate cancers. In addition, some studies have shown that the levels of ATP-hydrolyzing are also increased in pre-malignant stages of cancer, which suggests that inhibitors of ATP-hydrolyzing may be an effective way to prevent cancer progression.

Conclusion

In conclusion, DNA topoisomerase (ATP-hydrolyzing) is a key enzyme in the process of DNA replication that has significant implications for cancer treatment. The discovery of new drug targets and biomarkers for this enzyme has the potential to improve the treatment of various types of cancer. Further research is needed to fully understand the role of ATP-hydrolyzing in cancer development and to develop effective strategies for inhibiting its activity.

Protein Name: DNA Topoisomerase II Alpha

Functions: Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand (PubMed:17567603, PubMed:18790802, PubMed:22013166, PubMed:22323612). May play a role in regulating the period length of BMAL1 transcriptional oscillation (By similarity)

The "TOP2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOP2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets